> Detailanzeige

Rotundo, Salvatore; Borelli, Massimo; Scaglione, Vincenzo; Lionello, Rosaria; Biamonte, Flavia; Olivadese, Vincenzo; Quirino, Angela; Morrone, Helen Linda; Matera, Giovanni; Costanzo, Francesco Saverio; Russo, Alessandro; Trecarichi, Enrico Maria; Torti, Carlo; Serapide, Francesca; Tassone, Bruno; Fusco, Paolo; Davoli, Chiara; La Gamba, Valentina; Morrone, Helen Linda; Berardelli, Lavinia; Tassone, Maria Teresa; Serraino, Riccardo; Costa, Chiara; Foti, Daniela Patrizia; [...]

Interleukin-62/lymphocyte as a proposed predictive index for COVID-19 patients treated with monoclonal antibodies

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Interleukin-62/lymphocyte as a proposed predictive index for COVID-19 patients treated with monoclonal antibodies
  • Beteiligte: Rotundo, Salvatore; Borelli, Massimo; Scaglione, Vincenzo; Lionello, Rosaria; Biamonte, Flavia; Olivadese, Vincenzo; Quirino, Angela; Morrone, Helen Linda; Matera, Giovanni; Costanzo, Francesco Saverio; Russo, Alessandro; Trecarichi, Enrico Maria; Torti, Carlo; Serapide, Francesca; Tassone, Bruno; Fusco, Paolo; Davoli, Chiara; La Gamba, Valentina; Morrone, Helen Linda; Berardelli, Lavinia; Tassone, Maria Teresa; Serraino, Riccardo; Costa, Chiara; Foti, Daniela Patrizia; [...]
  • Erschienen: Springer Science and Business Media LLC, 2023
  • Erschienen in: Clinical and Experimental Medicine
  • Sprache: Englisch
  • DOI: 10.1007/s10238-023-01081-6
  • ISSN: 1591-9528
  • Schlagwörter: General Biochemistry, Genetics and Molecular Biology ; General Medicine
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <jats:title>Abstract</jats:title><jats:p>In a convenience sample of 93 patients treated with monoclonal antibodies (moAbs) against SARS-CoV-2, the interleukin-6<jats:sup>2</jats:sup>/lymphocyte count ratio (IL-6<jats:sup>2</jats:sup>/LC) was able to predict clinical worsening both in early stages of COVID-19 and in oxygen-requiring patients. Moreover, we analysed 18 most at-risk patients with asymptomatic or mild disease treated with both moAbs and antiviral treatment and found that only 2 had clinical progression, while patients with a similar risk were reported to have an unfavourable outcome in most cases from recent data. In only one of our 18 patients, clinical progression was attributable to COVID-19, and in the other cases, clinical progression was observed despite IL-6<jats:sup>2</jats:sup>/LC being above the risk cut-off. In conclusion, IL-6<jats:sup>2</jats:sup>/LC may be a valuable method to identify patients requiring more aggressive treatments both in earlier and later stages of the disease; however, most at-risk patients can be protected from clinical worsening by combining moAbs and antivirals, even if levels of the IL-6<jats:sup>2</jats:sup>/LC biomarker are lower than the risk cut-off.</jats:p>